Possible Role of Interleukin-31/33 Axis in Imatinib Mesylate-Associated Skin Toxicity

Possible Role of Interleukin-31/33 Axis in Imatinib Mesylate-Associated Skin Toxicity

Imatinib mesylate is a small-molecule tyrosine kinase inhibitor (TKi) designed to target c-ABL and BCR-ABL, approved for the treatment of chronic myeloid leukemia and gastrointestinal stromal tumors. Adverse cutaneous reactions induced by imatinib are frequent, generally moderate, and dose-dependent...

Full description

Bibliographic Details
Main Authors: Caterina Musolino, Alessandro Allegra, Carmen Mannucci, Sabina Russo, Andrea Alonci, Valerio Maisano, Gioacchino Calapai, Sebastiano Gangemi
Format: Article
Language:English
Published: Galenos Publishing House 2015-05-01
Series:Turkish Journal of Hematology
Subjects:
interleukin-31 (il-31)
interleukin-33 (il-33)
tyrosine kinase inhibitors
imatinib mesylate
chronic myeloid leukemia
pruritus
Online Access:https://jag.journalagent.com/z4/download_fulltext.asp?pdir=tjh&un=TJH-76402

Internet

https://jag.journalagent.com/z4/download_fulltext.asp?pdir=tjh&un=TJH-76402

Similar Items